2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018, 61: 2118-2125. PMID: 30132031, DOI: 10.1007/s00125-018-4663-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsWeight LossConceptsSGLT2 inhibitorsSodium-glucose cotransporter 2 inhibitorsPostprandial blood glucose levelsEuglycaemic diabetic ketoacidosisGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetic kidney diseaseGenitourinary tract infectionsLower extremity amputationHigh-risk individualsBlood glucose levelsPlasma glucose concentrationCardiovascular outcomesDiabetic ketoacidosisUrinary frequencyTract infectionsOptimal prescribingNew drug categoryKidney diseaseGlucose reabsorptionGlucose levelsHigh riskDrug categoriesBody weightBone fractures
2015
Bone Health and Osteoporosis
Lupsa BC, Insogna K. Bone Health and Osteoporosis. Endocrinology And Metabolism Clinics Of North America 2015, 44: 517-530. PMID: 26316240, DOI: 10.1016/j.ecl.2015.05.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone healthBone lossLow bone massAdditional risk factorsDual-energy X-ray absorptiometry measurementsLow-energy fracturesBone mineral densityMicroarchitectural deteriorationEstrogen levelsSmoking cessationRisk factorsMineral densityPharmacologic agentsBone massHigh riskOlder womenWomen's ageBone strengthAbsorptiometry measurementsOsteoporosisGold standardBone tissueRiskHealthFractures